Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
Programmed cell death 1(PD-1)/programmed cell death ligand 1(PD-L1) have emerged as one of the most promising immune checkpoint targets for cancer immunotherapy. Despite the inherent advantages of small-molecule inhibitors over antibodies, the discovery of small-molecule inhibitors has fallen behind...
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
格式: | Article |
語言: | English |
出版: |
Elsevier
2022-12-01
|
叢編: | Acta Pharmaceutica Sinica B |
主題: | |
在線閱讀: | http://www.sciencedirect.com/science/article/pii/S2211383522001770 |